Robert (Albert) Schupp-Market Access Consultant
Experience
External Consultant Market Access Germany
Paion Pharma GmbH
- Secured market access for 3 ICU products and supported a relaunch
- Led projects and provided strategic advice for the preparation and submission of the AMNOG benefit assessment for Byfavo® in sedation
- Trained and supported KAMs on regional market access
External Consultant Market Access Germany
CSL Behring
- Led the preparation and provided strategic advice for the AMNOG process, including price and reimbursement for the orphan drug Garadacimab in HAE
- Collaborated closely with global and regional market access teams to ensure alignment with European and corporate strategies
- Monitored health policy developments, HTA trends, and reimbursement landscapes to inform local access strategies
General Manager DACH
Gensight Biologics
- Built trusted relationships with key stakeholders in Germany and Austria, especially health authorities, KOLs, and patient advocacy groups
- Expedited early access for the gene therapy Lumevoq® in ophthalmology and drove pre-launch campaigns for this ATMP
- Translated clinical and economic evidence into compelling value arguments tailored to the German healthcare system
- Built the network of gene therapy centers, addressing stringent quality control requirements
General Manager DACH
Santhera
- Built and led a cross-functional team and regional affiliate to commercialize an ultra-orphan drug for mitochondrial and neuromuscular diseases
- Successfully launched and secured market access (AMNOG and price negotiations with GKV-SV) for the lead compound Raxone® in Leber's hereditary optic neuropathy (LHON)
- Achieved consistent growth, peaking at 39% year-over-year growth in 2019
- Established the first patient registry in LHON
- Timely achieved launch readiness in initial countries for entering the Duchenne muscular dystrophy market with the new brand Puldysa®
General Manager DACH
Synageva BioPharma
- Focused on all aspects of building an ultra-rare disease franchise, including establishing a strong disease awareness campaign for LAL deficiency and setting up regional infrastructure to support market access and launch
- Extensively engaged with academia, physicians, and patient advocacy groups to drive testing and identification of the patient population
Executive Director Biomarker & Diagnostics Hematology/Oncology
Celgene International
- Developed and implemented an overall biomarker and diagnostic strategy within the global cross-functional team and external stakeholders
- As a member of the global brand team, created EU market entry and brand plan to prepare launch of Imnovid® in myelofibrosis
- Contributed to the global business development team and evaluated new business opportunities in the EU (new NCEs and/or co-operations)
- Built a solid ecosystem with external stakeholders through speaker participation at industry associations and biomarker congresses
General Manager
Celgene GmbH
- Led a dynamically growing franchise of 300 M USD and 140 employees; managed two business units (hematology and oncology), finance, HR, external communications, market access & reimbursement, medical department
- Member of the EU management committee and several task forces, including EMEA central warehouse project and pomalidomide prelaunch team
- Developed and implemented a strategic plan to leverage the orphan drug portfolio and achieved exceptional evaluation within AMNOG
- Led the healthcare-economics task force of BioDeutschland and executed several key governmental affairs initiatives in rare diseases
- Surpassed revenue and margin goals, generated double-digit growth year over year and secured fastest growing affiliate status in the EU5
- Built up a new oncology business unit and successfully re-launched Abraxane® in the highly competitive breast cancer market
Director Sales & Marketing
Celgene GmbH
- Built and led high-performance sales, marketing and market access organizations from the ground up and established impactful operations
- Developed and executed CRM strategy, gaining trust of key opinion leaders, payers and patient advocacy groups towards a start-up company
- Established the first NPP for a contergan derivative
- Successfully launched Revlimid® in a competitive market, achieving market leadership within two years
- Launched Thalidomide® and Vidaza® drugs successfully
- Led smooth post M&A integration of Pharmion business and staff
Manager Distributor Operations in 9 EU countries
Abbott International / Hospira BV
- Led and project-managed the spin-off of Abbott’s hospital business, overseeing a diverse portfolio of critical care and i.v. generic products
- Negotiated with distributors and affiliate Abbott senior leadership
- Established distributor network in nine countries, negotiated contracts with selected partners, established metrics and monitored progress versus goals
- Achieved successful spin-off by the SEC deadline
- Rolled out autonomous regional operations on time
General Manager
Wolters Kluwer Health
- Spearheaded organizational transformation into a locally managed subsidiary and reengineered affiliate governance structure
- Created short- and long-term business growth plans
- Achieved significant sales growth: +26% versus plan and +5% versus prior year
General Manager ad interim
Foundation for Living of the Elderly
- Developed cost center system and balance sheet for 2002
- Prepared expense plan and conducted the annual lodgers meeting
Business Unit Manager Oncology & Hematology
Schering-Plough
- Led two hematology and oncology business units, marketing a portfolio of five oncology drugs and overseeing a team of up to 60; managed P&L for €70 M with double-digit growth rates
- Led major field force restructuring and organizational change
- Implemented a program to compete with parallel imports including sales force, service level, CRM project and targeted rebating
- Worked within the corporate oncology task force and contributed to the SBU portfolio and generic defense strategy
- Developed and implemented short- and long-range strategic plans and annual business and medical affairs plans
- Successfully launched two new drugs (Temodal®, Caelyx®) and established a co-promotion partnership with Grünenthal on a buprenorphine patch (Transtec®)
- Secured endorsement of high-dose interferon (Intron® A) therapy by the German Dermatology Association
- Initiated high-profile multi-institutional trials, e.g. CML-4 study
European Product Manager Immunoselection
BAXTER Healthcare
- Developed and implemented annual strategic and brand plans
- Managed research and clinical projects, including design and data collection
- Organized international symposia and conducted customer training programs in-house and on-site
- Launched several line extensions of ISOLEX®
BU-Manager Immunotherapy Europe
BAXTER Healthcare
- Directed sales, budget and P&L responsibility for several medical device products for clinical use of bone marrow or peripheral blood
- Licensed, acquired and launched a diagnostic kit in breast cancer
- Served as commercial leader for the EMEA sales team; established a cross-functional team to serve transplant units, blood banks and centers of excellence
- Tripled sales in five years, achieved market leadership in the selection market and reached divisional break-even
- Managed smooth transition of immunoselection business to a joint venture partner, Nexell Therapeutics, USA
Sales Representative Hematology
AMGEN
- Generated €1 M in annual Neupogen® sales and ranked #2 of 10
- Contributed to the first development of PBSCT in myeloma at a center of excellence
Industry Experience
See where this freelancer has spent most of their professional time.
Experienced in Pharmaceutical, Biotechnology, and Healthcare.
Business Area Experience
See which departments and functions this freelancer has contributed to most.
Experienced in Marketing, Sales, Strategy, Product Development, Operations, and Project Management.
Summary
- 30+ years’ industry experience with extensive experience in rare diseases/ orphan drugs
- At Celgene Germany, set up and built out their Market Access department (in response to new AMNOG legislation) and worked across their portfolio in hematology and oncology.
- At Santhera, led the DACH Market Access workstream for the rare disease portfolio; launched RAXONE (orphan ophthalmology asset) in LHON, achieved launch readiness for PULDYSA in DMD.
- At GenSight, ensure launch readiness, with a primary focus on market access of their ultra-orphan gene therapy product LUMEVOQ, esp. regarding early payer engagement, contracting, national HTA submissions and new regulations for ATMPs
- Member of the DFGMA (German Society for Market Access)
- Motivation: I want to leverage my broad and deep expertise in market access and provide ad-hoc support and on-demand interim management. I have a passion for working with people to help launch innovative products in areas of high unmet need
Skills
- Teaching Experience: Trainer At The University Of Cologne And At A College
Languages
Education
European Business School (EBS)
Postgraduate study · Market Access Management · Oestrich-Winkel, Germany · Grade 1.4
University of Cologne
MBA - Postgraduate study · Business Administration · Cologne, Germany · Grade: Good
Technical University of Munich
Ph.D. · Biochemistry · Munich, Germany · summa cum laude
Certifications & licenses
First State Examination for Secondary Level II Teaching Certification
State Examination Office for First State Examinations for School Teaching Degrees
Professional Part of the Non-Commissioned Officer Examination
Academy of Medical and Health Services of the German Armed Forces
ATN 0380
Medical Service Examination
Statistics
Experience
Global Experience
Expertise
Qualifications
Profile
Frequently asked questions
Do you have questions? Here you can find further information.
Where is Robert based?
What languages does Robert speak?
How many years of experience does Robert have?
What roles would Robert be best suited for?
What is Robert's latest experience?
What companies has Robert worked for in recent years?
Which industries is Robert most experienced in?
Which business areas is Robert most experienced in?
Which industries has Robert worked in recently?
Which business areas has Robert worked in recently?
What is Robert's education?
Does Robert have any certificates?
What is the availability of Robert?
What is the rate of Robert?
How to hire Robert?
Average rates for similar positions
Rates are based on recent contracts and do not include FRATCH margin.
Similar Freelancers
Discover other experts with similar qualifications and experience
Experts recently working on similar projects
Freelancers with hands-on experience in comparable project as a External Consultant Market Access Germany
Nearby freelancers
Professionals working in or nearby Tutzing, Germany
Most recent projects
FRATCH works with many companies and recruitment agencies. Here you will find our recently posted projects and opportunities.